Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Depreciation (2018 - 2024)

Bicycle Therapeutics' Accumulated Depreciation history spans 7 years, with the latest figure at $16.6 million for Q2 2024.

  • For Q2 2024, Accumulated Depreciation rose 59.03% year-over-year to $16.6 million; the TTM value through Jun 2024 reached $16.6 million, up 59.03%, while the annual FY2023 figure was $13.4 million, 70.33% up from the prior year.
  • Accumulated Depreciation reached $16.6 million in Q2 2024 per BCYC's latest filing, up from $14.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $16.6 million in Q2 2024 to a low of $2.8 million in Q1 2020.
  • Average Accumulated Depreciation over 5 years is $7.3 million, with a median of $5.1 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation: increased 15.09% in 2022, then skyrocketed 101.58% in 2023.
  • A 5-year view of Accumulated Depreciation shows it stood at $4.0 million in 2020, then grew by 19.05% to $4.8 million in 2021, then skyrocketed by 63.81% to $7.9 million in 2022, then surged by 70.33% to $13.4 million in 2023, then rose by 23.99% to $16.6 million in 2024.
  • Per Business Quant, the three most recent readings for BCYC's Accumulated Depreciation are $16.6 million (Q2 2024), $14.9 million (Q1 2024), and $13.4 million (Q4 2023).